p53-targeted cancer pharmacotherapy: Move towards small molecule compounds

Full text for this resource is not available from the Research Repository.

Kim, Soo-Hyun and Dass, Crispin R (2011) p53-targeted cancer pharmacotherapy: Move towards small molecule compounds. Journal of Pharmacy and Pharmacology, 63 (5). pp. 603-610. ISSN 0022-3573


Objectives For the past three decades of research, p53 has been identified as one of the most targetable molecules for developing anticancer treatments. This tumour suppressor protein is involved in apoptosis, cell cycle arrest and senescence. A wide range of pharmaceutical drugs and radiotherapy treatments activate this protein and rely on p53 signalling for therapeutic outcome. Promising small molecular weight compounds, some of which are undergoing clinical trials, are discussed in this review. Key findings The spectrum of potential therapeutic approaches trialled for p53 stretch from gene therapy to the more recent development of small molecules capable of activating wild-type p53 or reactivating mutant p53. Summary Our ever-growing knowledge leads us to better understand this protein, from its structure and activities to its potential therapeutic application, firstly for cancer and then for other diseases and maybe even for reversal of ageing.

Dimensions Badge

Altmetric Badge

Item type Article
URI https://vuir.vu.edu.au/id/eprint/10427
DOI 10.1111/j.2042-7158.2010.01248.x
Official URL http://onlinelibrary.wiley.com/doi/10.1111/j.2042-...
Subjects Historical > Faculty/School/Research Centre/Department > School of Biomedical and Health Sciences
Historical > FOR Classification > 1112 Oncology and Carcinogenesis
Keywords ResPubID24989, apoptosis, cancer, chemotherapy, drug, p53, tumour, Li–Fraumeni syndrome, tumour suppressor gene, gene therapy, DNA damage, fatty acid synthase gene, FAS gene, osteosarcoma
Citations in Scopus 10 - View on Scopus
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login